INTRODUCTION
============

Type 2 diabetes mellitus (T2DM) is a risk factor for cardiovascular disease (CVD), and T2DM patients are at increased risk of morbidity and mortality from CVD \[[@B1]\]. The presence of T2DM also increases the relative risk (RR) of developing CVD in women (RR = 8.5) compared to men (RR = 3.2) \[[@B1]\]. Major CVD risk factors that have been identified in T2DM patients include arterial stiffening \[[@B2]\], endothelial dysfunction \[[@B3]\], hyperglycemia \[[@B4]\], and elevated glycated haemoglobin (HbA1c) concentrations \[[@B5]\]. The UK Prospective Diabetes Study has showed that tight control of blood pressure and blood glucose concentration among T2DM patients does not reduce risk of myocardial infarction and peripheral vascular disease \[[@B6]\].

High levels of homocysteine (Hcys) have been identified as a risk factor for CVD in T2DM patients \[[@B7]\]. High concentrations of Hcys are associated with increased low-density lipoprotein oxidation \[[@B8]\] and endothelial dysfunction \[[@B9]\]. High concentrations of Hcys can worsen T2DM by inducing reversible dysfunction of β-islet cells \[[@B10]\] and inhibiting secretion of insulin \[[@B11]\]. Levels of plasma Hcys increase in women after menopause, and post-menopausal diabetic women are consequently at significantly increased risk of CVD \[[@B12][@B13]\].

Folic acid supplementation may improve the cardiovascular health of post-menopausal women with diabetes. In particular, folic acid supplementation has been shown to reduce Hcys levels and improve vascular health in different study populations. Studies have also shown that folic acid supplementation can slow progress of atherosclerosis \[[@B14]\], improve plasma folate levels, and reduce plasma Hcys levels \[[@B15]\]. Folic acid supplementation also improves vascular parameters in post-menopausal women \[[@B16]\]. Further, studies on healthy, post-menopausal Egyptian \[[@B13]\], Italian \[[@B17]\], and Pakistani \[[@B18]\] women have shown that folic acid supplementation improves Hcys levels. Similarly, several studies have reported that folic acid supplementation can improve Hcys levels among T2DM patients \[[@B19]\] and post-menopausal women at high risk of developing CVD \[[@B20]\]. However, to our knowledge, no such studies have examined the post-menopausal diabetic female population, particularly in South-east Asia.

From the 1990s to 2013 in Korea, there has been an increase in T2DM incidences from 7.2% to 11% \[[@B21]\]. Though the CVD mortality rate has decreased in Korea over the past decade, the disease burden remains high \[[@B22]\]. Thus, this study aimed to investigate whether or not folic acid supplementation can lower Hcys levels and improve vascular parameters in post-menopausal diabetic Korean women.

SUBJECTS AND METHODS
====================

Study subjects
--------------

The participants in this study included female patients with T2DM who visited Huh\'s Diabetes Clinic in Seoul, Korea. Between September 2005 and February 2011, 854 patients visited the clinic \[[@B21]\]. For this study, post-menopausal women aged 56-74 years with amenorrhea for over 24 months and serum Hcys ≥ 10 µmol/L were considered. The top 20^th^ percentile of serum Hcys among our participants was 10 µmol/L. Thus, serum Hcys ≥ 10 µmol/L was used as the inclusion criterion. The participants received treatment for T2DM; other medications and diet therapy remained unchanged during the study period. Exclusion criteria included receiving hormone replacement therapy or having consumed folic acid supplements in the past 12 weeks. During the consultation time, study participants were advised to not make any changes in their lifestyle behaviors such as dietary habits. The 31 participants in this study consumed 800 µg of folic acid daily (400 µg twice a day) for 8 weeks. In this study, no side effects were reported. Overall, 81% (n = 25) of participants had \> 70% compliance and were included in this statistical analysis. The remaining quantity of folic acid tablets was used to estimate the compliance rate of the study participants. Thus, the total number of participants eligible for the final analysis was 25. All participants volunteered for the study, and informed consent was obtained. The research protocol was approved by the Institutional Review Board of Ewha Womans University, Seoul, Korea (IRB No. 100-3).

General characteristics
-----------------------

Information on age, education, employment status, smoking habits, alcohol consumption, exercise pattern, duration of T2DM, family history of diabetes, and hypertensive and hyperlipidemia status was collected through questionnaires. The standing heights of the participants were measured using a stadiometer (Seca Inc., Hamburg, Germany). The body weights of the participants were measured using InBody 4.0 (Biospace Co., Ltd, Seoul, Korea). Body mass index (BMI; kg/m^2^) was calculated using height and weight measurements.

Folic acid supplementation and dietary assessment
-------------------------------------------------

In this study, 800 µg of folic acid daily (400 µg twice a day) for 8 weeks was administered to the study participants. A folic acid supplementation study among the Netherlands population, including post-menopausal women aged 50-70 years administered 800 µg of folic acid to the study participants for 3 years \[[@B23]\]. The Korean dietary reference intake (DRI) recommends 1,000 µg per day as the tolerable upper intake levels for folic acid intake. Supplementation with 800 µg of folic acid was carried out based on compliance with Korean DRI recommendations and the existing literature.

The mini dietary assessment (MDA) questionnaire was used to assess dietary habits among the study subjects before and after supplementation. The MDA questionnaire was in Korean and consisted of a total of 10 components. The questionnaire collected data about the participants\' dietary habits, including daily intake of dairy products, fish and meat consumption, vegetable and fruit intake, as well as consumption of fatty and salty foods and confectionaries. In the questionnaire, four components consisted of encouraged behaviors while three components consisted of restricted behaviors. The answer choices were "always," "generally," and "seldom." For the four encouraged components, the answer choice "always" received a score of 5, "generally" a score of 3, and "seldom" a score of 1. The score points were reversed for restricted components. The total scores from each question were calculated to obtain the dietary habit score, and the total possible score was 50.

Blood analyses
--------------

Blood samples were drawn from the participants after a 12-hour overnight fast. The samples were collected in tubes containing Ethylenediaminetetraacetic acid, followed by centrifugation at 3,000 rpm for 20 min at 4℃ (Hanil Science Industrial Co., Ltd, Seoul, Korea). Serum folate, vitamin B~12~, and Hcys were measured using chemiluminescence immunoassays (ADVIA Centaur XP, Siemens Healthcare Diagnostic, USA). Triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and fasting blood sugar (FBS) were measured using an autoanalyzer (Cobas Mira Roche, Hoffmann-La Roche Ltd., Basel, Switzerland). The following equation, developed by Friedewald \[[@B24]\] and Lauer \[[@B25]\], was used to calculate low-density lipoprotein cholesterol (LDL-C) levels.

Measurements of HbA1c were taken using an autoanalyzer (HLD-723 G7, Tosoh Corporation, Tokyo, Japan).

Vascular parameter measurements
-------------------------------

After allowing the participants to rest for 10 min, systolic blood pressure (SBP) and diastolic blood pressure (DBP) measurements were taken in a sitting position using an automatic blood-pressure monitor (Biospace Co., Seoul, Korea). The average of the SBP and DBP measured from the left and right arms was used for the analyses.

The moving pulse wave velocity between two different points on the ankle and brachial artery was measured using an automated analyzer (VP-1000; Colin Co. Ltd., Komaki, Japan). Brachial-ankle pulse wave velocity (baPWV) was calculated further using the moving pulse wave velocity between the ankle and brachial artery and the following equation based on transmission distance, which was calculated based on the subject\'s height \[[@B26]\].

The average value of the left and right baPWV was used in the analyses. Blood pressures of the ankle and brachial arteries were measured using a bidirectional Doppler (BiDop ES-100V, Koven Technology, St. Louis, USA) and mercury sphygmomanometer \[[@B27]\]. The ankle SBP value was divided by the brachial SBP value to obtain the ankle brachial index (ABI) for the respective leg \[[@B27]\]. The average ABI values from the left and right legs were used for the analysis. Radial pulse was measured for 15 seconds in a seated position after resting for 5 minutes. The value was then multiplied by 4 to obtain pulse rate (beats/min). The average pulse rate of the left and right hands was used for the analysis.

Statistical analyses
--------------------

General characteristics of the subjects were expressed as means ± SD (continuous data) or as numbers with percentages (categorical data). The paired t-test was used to determine differences in mean anthropometric and clinical characteristics before and after folic acid supplementation. For further analysis, data were categorized using the following cut-off values: SBP ≥ 130 mmHg, DBP ≥ 85 mmHg, FBS ≥ 100 mg/dL, TG ≥ 150 mg/dL, TC ≥ 240 mg/dL, HDL-C \< 50 mg/dL, LDL-C ≥ 70 mg/dL, LDL-C/HDL-C \> 2 \[[@B28]\], TC/HDL-C \> 3 \[[@B28]\], TG/HDL-C \> 4 \[[@B29]\], HbA1c \> 6%, Hcys ≥ 15 µmol/L, folate \< 7.0 ng/mL \[[@B30]\], vitamin B~12~ \< 300 pg/mL, ABI \< 1.0 \[[@B31]\], baPWV ≥ 1,566 cm/s \[[@B32]\], and pulse rate \> 60 beats/min. McNemar\'s test was used to analyze changes in anthropometric and clinical characteristics before and after folate supplementation. Pearson\'s correlation test was performed to evaluate the relationship between changes in Hcys, folate, vitamin B~12~, and other variables after supplementation. All statistical analyses were performed using the SAS statistical package (SAS 9.3, SAS Institute Inc., Cary, NC, USA). The level of significance set for the study was *P* \< 0.05.

RESULTS
=======

General characteristics of the participants
-------------------------------------------

The mean age of the participants was 66.0 ± 5.5 years ([Table 1](#T1){ref-type="table"}). The mean BMI of the participants before supplementation was 24.3 ± 3.5 kg/m^2^. The mean duration of diabetic status was 13.4 ± 5.4 years, and 55.0% of participants had a family history of diabetes. Among the participants, 95.5% were non-smokers.

Anthropometric and clinical characteristics before and after folic acid supplementation
---------------------------------------------------------------------------------------

There was no significant difference (*P* = 0.8647) in mean MDA scores before (34.3 ± 4.7) and after supplementation (33.8 ± 5.3) ([Table 2](#T2){ref-type="table"}). Further, there were no significant changes in weight and BMI after supplementation.

There was a significant increase in serum folate levels, from 14.1 ± 6.6 ng/mL to 44.4 ± 9.6 ng/mL, after supplementation (*P* \< 0.0001) ([Table 2](#T2){ref-type="table"}). Serum vitamin B~12~ levels also significantly increased by 16.2% from 528.2 ± 176.7 pg/mL to 613.7 ± 176.0 pg/mL after supplementation (*P* = 0.0027). There was a 22.2% decrease in serum Hcys levels after supplementation from 15.3 ± 3.8 µmol/L to 11.9 ± 2.6 µmol/L (*P* \< 0.0001). The baseline values for vitamin B~12~, TG, TC, HDL-C, TG/HDL-C ratio, and DBP were within healthy cut-off values. After folic acid supplementation, mean serum Hcys was within the healthy range of \< 15 µmol/L. There were no significant changes in the vascular parameters baPWV and pulse rate after folic acid supplementation. Folic acid supplementation reduced LDL-C level (*P* = 0.0018) as well as LDL-C/HDL-C and TC/HDL-C ratios. No significant changes were observed in other clinical parameters, including BMI, SBP, FBS, HbA1c, TG, and HDL-C.

Clinical characteristics before and after folic acid supplementation using cut-off values
-----------------------------------------------------------------------------------------

Clinical characteristics before and after folic acid supplementation were compared using cut-off values. Clinical characteristics for which significant results were observed are presented in [Table 3](#T3){ref-type="table"}. The number of participants with Hcys ≥ 15 µmol/L decreased from 9 (36.0%) to 3 (12.0%) after folic acid supplementation.

Association between changes in clinical characteristics before and after supplementation
----------------------------------------------------------------------------------------

Correlation analysis for changes in clinical characteristics before and after supplementation found significant changes only in serum Hcys, folate, serum vitamin B~12~, and baPWV levels (data not shown). An inverse correlation (r = -0.4876, *P* = 0.0134) was observed between changes in serum Hcys and folate levels after supplementation ([Fig. 1](#F1){ref-type="fig"}). An inverse correlation between changes in serum vitamin B~12~ and baPWV levels (r = -0.4153, *P* = 0.0390) ([Fig. 2](#F2){ref-type="fig"}) was also observed after 8 weeks of folic acid supplementation.

DISCUSSION
==========

The effects of folic acid supplementation on Hcys levels and vascular parameters in post-menopausal Korean women with T2DM were investigated. Daily supplementation with 800 µg of folic acid for 8 weeks significantly improved serum Hcys, folate, and vitamin B~12~ levels as well as lipid parameters, including LDL-C level as well as LDL-C/HDL-C and TC/HDL-C ratios. Folic acid supplementation did not improve the vascular parameter baPWV.

Several other studies have reported increased folate and vitamin B~12~ levels and reduced Hcys levels after folic acid supplementation. Folic acid supplementation in post-menopausal women or T2DM or coronary heart disease patients has been associated with increased folate levels \[[@B15][@B16][@B19]\]. Hcys levels were shown to be reduced in healthy Egyptian and Italian post-menopausal women after folic acid supplementation \[[@B13][@B17]\]. Folic acid is an essential vitamin cofactor required for the remethylation of Hcys to methionine in the Hcys metabolism pathway \[[@B33][@B34]\]. The serum vitamin B~12~ level in our subjects increased significantly by 16.2% after folic acid supplementation. Another folic acid supplementation study on healthy postmenopausal women reported a non-significant 2% increase in serum vitamin B~12~ levels \[[@B17]\]. Vitamin B~12~ is another important vitamin cofactor necessary for the remethylation of Hcys \[[@B34]\]. High Hcys levels trap vitamin B~12~, which becomes bound to methionine synthase as methyl-cobalamin \[[@B35]\]. The increase in remethylation of Hcys to methionine after folic acid supplementation releases vitamin B~12~ from methionine synthase, thereby increasing levels of vitamin B~12~. Folic acid supplementation was thus able to increase remethylation of Hcys and reduce accumulation of Hcys by increasing serum folate and vitamin B~12~ levels. In our study, mean serum Hcys level was within the healthy range of \< 15 µmol/L after supplementation. Changes in biochemical parameters before and after folic acid supplementation were also analyzed using appropriate cut-off values. Before folic acid supplementation, 36% of our study participants had hyperhomocysteinemia, which was reduced to 12% by the end of the study. Studies have shown that an increase in Hcys levels to 15-25 µmol/L can be attributed to dietary deficiencies in folic acid and vitamins B~6~ and B~12~ \[[@B33][@B36]\].

Folic acid supplementation significantly reduced LDL-C levels as well as LDL-C/HDL-C and TC/HDL-C ratios in this supplementation trial. Further, analysis using cut-off values reported significant reduction of LDL-C/HDL-C ratio (\> 2 value) in participants. In our study, 70.8% of the population had hyperlipidemia. The current literature has not stratified subjects based on medication status for analysis \[[@B37]\]. In our study, there were no significant changes in weight, BMI, and dietary habit score in MDA after 8 weeks of folic acid supplementation. However, there were 7.5% and 14.3% reductions in LDL-C levels and LDL-C/HDL-C ratios, respectively, after supplementation. A study on healthy post-menopausal Italian women similarly observed a 27.5% reduction in LDL-C/HDL-C ratio after folic acid supplementation \[[@B17]\]. An experimental study on cystathionine-β-synthase^-/-^/apolipoprotein E^-/-^ mice reported an association between higher Hcys levels as well as decreased HDL-C and increased TC and non-HDL-C levels \[[@B38]\]. High Hcys levels were also shown to reduce the enzymatic activities of two HDL-metabolism related enzymes, hepatic thiolase and lecithin-cholesterol acyltransferase \[[@B39]\]. Increased levels of Hcys were shown to induce mitochondrial stress, leading to an increase in the expression of sterol regulatory element-binding protein increasing expression of LDL receptors and LDL-C uptake \[[@B40]\]. The improvements in lipid parameters might be due to the reduction of serum Hcys levels caused by folic acid supplementation. Vitamin B~12~ deficiency in patients with T2DM taking metformin, a standard drug treatment for T2DM, has been well established. Circulating vitamin B~12~ level was shown to be reduced by 25% when using metformin, which is inversely correlated with lipid profile parameters such as TG level and TC/HDL-C ratio \[[@B41]\]. The role of vitamin B~12~ as a coenzyme for fatty acid oxidation is affected by vitamin B~12~ deficiency, resulting in lipogenesis and accumulation of lipids \[[@B41]\]. The 16.2% increase in serum vitamin B~12~ level in our study after supplementation could have caused reduction of LDL-C level through increased fatty acid oxidation.

Pulse wave velocity (PWV), a measure of arterial stiffness \[[@B42]\] and distensibility \[[@B32]\], is regarded as an indicator of vascular health \[[@B42]\]. In the present study, we observed no change in the vascular parameter baPWV after folic acid supplementation. Another folic acid supplementation study on T2DM patients also reported no significant improvement in carotid-radial and carotid-femoral PWV after 4 weeks \[[@B42]\]. Several studies performed flow-mediated dilation to investigate improvement of vascular parameters after folic acid supplementation. Folic acid supplementation was shown to improve flow-mediated dilation in post-menopausal women \[[@B16]\] and coronary heart disease patients \[[@B15]\]. Lowered Hcys levels might improve endothelial function, as increased plasma Hcys levels are associated with endothelial dysfunction through activation of coagulation factors, changes in adhesive properties of the endothelial surface \[[@B43]\], and increased oxidation of LDL-C \[[@B44]\].

In our study, we observed a significant inverse relationship between changes in vitamin B~12~ level and baPWV. Other researchers reported a significant inverse relationship between vitamin B~12~ and PWV in T2DM patients \[[@B42]\]. The mechanism responsible for the increase in vitamin B~12~ and decrease in baPWV is unclear but might be related to asymmetrical dimethylarginine (ADMA). ADMA has been identified as a competitive endogenous inhibitor of nitric oxide synthase, a necessary enzyme for nitric oxide synthesis \[[@B45][@B46]\]. Increased ADMA levels have been associated with increased PWV \[[@B47]\] and endothelial dysfunction \[[@B46]\]. Methylation of L-arginine-containing proteins produces ADMA \[[@B46]\]. The methyl source for this methylation process, which eventually produces Hcys, is S-adenosylmethionine \[[@B46]\]. Vitamin B~12~ plays an important role in the remethylation of Hcys to S-adenosylmethionine. Further, vitamin B~12~ supplementation studies have reported that vitamin B~12~ reduces levels of ADMA \[[@B45][@B48]\]. This reduction of ADMA caused by an increase in vitamin B~12~ levels might have led to the inverse association between changes in vitamin B~12~ level and baPWV.

This folic acid supplementation study has some limitations. This was a non-randomized trial, and the small sample size of the study (n = 25) might account for the lack of statistically significant changes in variables such as baPWV. Furthermore, the non-randomized study design and small sample size makes it difficult to generalize the study results. Further, the lack of a placebo control prevents any determination on whether or not the results were due to supplementation alone. Lack of dietary information, such as 24-hour dietary recall data, makes it difficult to understand how individual dietary habits may have interacted with supplementation. In our study, there was a lack of information on medications taken by the participants, which made determination of the possible interactions between supplementation, medications, and other dietary nutrients challenging. Nevertheless, this is the first study to investigate the effects of folic acid supplementation on Hcys levels and vascular parameters among post-menopausal Korean women with T2DM.

In conclusion, folic acid supplementation might be beneficial for reducing Hcys levels and decreasing lipid parameters in post-menopausal women with T2DM. We observed that folic acid supplementation reduced serum Hcys levels, increased serum folate and vitamin B~12~ levels, and lowered lipid parameters such as LDL-C levels as well as LDL-C/HDL-C and TC/HDL-C ratios. In our study, changes in serum vitamin B~12~ levels as a result of supplementation were inversely correlated with changes in baPWV. In the future, further analysis of folic acid supplementation, Hcys levels, and vascular parameters among post-menopausal Korean women using a larger sample size and randomization is necessary. Placebo control or collection of 24-hour food recall data will help differentiate between the effects of daily food intake and changes due to folate supplementation.
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###### General characteristics of post-menopausal women with diabetes at baseline
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^1)^Values are means ± SD or n (%).

###### Anthropometric and biochemical parameters before and after supplementation with folic acid in post-menopausal diabetic women
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MDA, mini dietary assessment; BMI, body mass index; Hcys, homocysteine; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; FBS, fasting blood sugar; HbA1c, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; baPWV, brachial-ankle pulse wave velocity; ABI, ankle brachial index.

^1)^Values are mean ± SD.

^2)^Paired t-test

###### Comparison of biochemical parameters to cut-off values before and after folic acid supplementation in post-menopausal diabetic women
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Hcys, homocysteine; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol.

^1)^Values are number of participants (percentage distribution).

^2)^McNemar\'s test
